Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of dapirolizumab pegol in systemic lupus erythematosus
2023-506368-14-00Phase 3Authorised
- Sponsor
- UCB
- Start
- Sep 2021
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 28
01
Overview
Phase 3, open-label, single-arm trial of dapirolizumab pegol in systemic lupus erythematosus (SLE), sponsored by UCB. Primary endpoints: Incidence of treatment-emergent adverse events, Incidence of serious treatment-emergent adverse events and 1 more. Planned start Sep 2021; status: authorised.
02
Drugs
dapirolizumab pegol
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2023-506368-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506368-14-00.